Advancements and Emerging Therapies in the Medical Management of Uterine Fibroids: A Comprehensive Scoping Review
- PMID: 38837949
- PMCID: PMC11163935
- DOI: 10.12659/MSM.943614
Advancements and Emerging Therapies in the Medical Management of Uterine Fibroids: A Comprehensive Scoping Review
Abstract
Uterine fibroids, benign tumors originating from uterine smooth muscle cells, vary in prevalence depending on patient ethnicity, hormonal exposure, and genetics. Due to their high incidence, these neoplasms pose a significant burden on healthcare systems. Current treatment strategies range from routine monitoring in asymptomatic cases to surgical procedures such as myomectomy or hysterectomy in symptomatic patients, with an increasing trend toward uterus-preserving or non-surgical alternatives. This review examines the existing medical treatments for uterine fibroids and delves into the potential of emerging therapies. A scoping review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. Medical therapies are divided into hormonal and non-hormonal treatments; however, long-term, safe, and effective treatments in the treatment of uterine fibroids are limited. In addition to established therapies, there is an increasing number of studies investigating the effect of substances such as vitamin D or green tea extract on uterine fibroids. Some studies investigate acupuncture as a possible alternative therapy. While existing treatments offer symptomatic relief and preparation for surgery, our findings point to a significant need for further research into long-term solutions, especially owing to recent limitations in the use of ulipristal acetate due to risk of liver damage. Initial studies involving vitamin D and epigallocatechin gallate are encouraging; however, additional research is required to establish definitive therapeutic roles.
Conflict of interest statement
Similar articles
-
The management of uterine leiomyomas.J Obstet Gynaecol Can. 2015 Feb;37(2):157-178. doi: 10.1016/S1701-2163(15)30338-8. J Obstet Gynaecol Can. 2015. PMID: 25767949
-
The management of uterine leiomyomas.J Obstet Gynaecol Can. 2003 May;25(5):396-418; quiz 419-22. J Obstet Gynaecol Can. 2003. PMID: 12738981
-
EMAS position statement: management of uterine fibroids.Maturitas. 2014 Sep;79(1):106-16. doi: 10.1016/j.maturitas.2014.06.002. Epub 2014 Jun 9. Maturitas. 2014. PMID: 24975954
-
Therapeutic management of uterine fibroid tumors: updated French guidelines.Eur J Obstet Gynecol Reprod Biol. 2012 Dec;165(2):156-64. doi: 10.1016/j.ejogrb.2012.07.030. Epub 2012 Aug 29. Eur J Obstet Gynecol Reprod Biol. 2012. PMID: 22939241 Review.
-
Uterine fibroid management: from the present to the future.Hum Reprod Update. 2016 Nov;22(6):665-686. doi: 10.1093/humupd/dmw023. Epub 2016 Jul 27. Hum Reprod Update. 2016. PMID: 27466209 Free PMC article. Review.
Cited by
-
Genetic and biomarker approaches to uterine fibroids: toward precision medicine.Front Glob Womens Health. 2025 Apr 22;6:1581823. doi: 10.3389/fgwh.2025.1581823. eCollection 2025. Front Glob Womens Health. 2025. PMID: 40330123 Free PMC article. Review.
-
The Roles of Non-Coding RNAs in the Pathogenesis of Uterine Fibroids.Cells. 2025 Aug 20;14(16):1290. doi: 10.3390/cells14161290. Cells. 2025. PMID: 40862769 Free PMC article. Review.
-
Linzagolix - new perspectives in the pharmacotherapeutic management of uterine fibroids and endometriosis.Prz Menopauzalny. 2025 Jun;24(2):126-130. doi: 10.5114/pm.2025.152947. Epub 2025 Jul 28. Prz Menopauzalny. 2025. PMID: 40777872 Free PMC article. Review.
References
-
- Szkodziak P, Pyra K, Szkodziak F, et al. The Lublin Protocol of the uterine arteries embolization in the treatment of symptomatic uterine fibroids. J Vis Exp. 2020;(163):61530. - PubMed
-
- Wang Y, Zhang S, Li C, Li B, Ouyang L. Minimally invasive surgery for uterine fibroids. Ginekol Pol. 2020;91(3):149–57. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical